EGFR TKIs vs CT

1. EGFR TKIs VS
CHEMOTHERAPY

2. Impact of Specific EGFR+ and Clinical Characteristics
on Outcomes After Treatment With EGFR TKIs Vs
Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-
Analysis.
• Aim: the impact of different EGFR mutations
and clinical characteristics on PFS in pts with
advanced EGFR-mutated NSCLC treated with
EGFR TKIs as 1st-line therapy.
• In seven eligible trials (N=1,649 patients)
Lee CK et al. J Clin Oncol. 2015 Apr 20. pii: JCO.2014.58.1736. [Epub ahead of print]

3. RESULT
• EGFR+ = For tumors with exon 19 deletions, the
benefit was 50% greater (HR, 0.24) than for
tumors with exon 21 L858R substitution (HR,
0.48; Pinteraction < .001).
• Never-smokers had a 36% greater benefit (HR,
0.32) than current or former smokers (HR, 0.50;
Pinteraction < .001).
• Women had a 27% greater benefit (HR, 0.33)
than men (HR, 0.45; treatment-sex interaction P =
.02).
Performance status, age, ethnicity, and tumor histology did not
significantly predict additional benefit from EGFR TKIs.

4. CONCLUSION
• EGFR TKIs significantly prolonged PFS overall
and in all subgroups, compared with
chemotherapy
• Greater benefits were observed in those with
exon 19 deletions, never-smokers, and
women.

5. Key points
• PFS benefit was increased for patients with
exon 19 deletion vs those with exon 21 L858R
substitution, never-smokers vs ever smokers,
and women vs men.
• Additional benefit was not predicted by
performance status, age, ethnicity, or
histology.